ClinicalTrials.gg
Sign In
RecruitingNCT03410394eurocrineUpdated Oct 22, 2026

Registry of Endocrine Tumors (Thyroid, Parathyroid, Adrenal, Endocrine Pancreas, Endocrine Digestive Tube)

An observational study in Endocrine Tumor, sponsored by Central Hospital, Nancy, France. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Central Hospital, Nancy, France · Observational

From the registry’s dates

  • Started Jan 2015; still recruiting 11 years 10 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,000
Sex
All
01

Study summary

This registry aims to collect informations about patients with endocrine tumors (Thyroid, Parathyroid, Adrenal, Endocrine Pancreas, Endocrine Digestive Tube) who undergo endocrine surgical procedures. This registry is part of the Eurocrine Project.

Read the detailed description

The EUROCRINE project aims to decrease morbidity and mortality of rare endocrine tumours, by means of a pan-European database. Recording and accessing data at the European level, makes it possible to identify these tumours, which cannot be distinguished at local or national level, because of their extreme rarity. Dissemination of results aims to raise clinical standards and reduce differences in practise between clinics and member states, and thereby diminish morbidity and mortality. Comparison of practice and outcomes will be especially interesting for centres wanting to improve their standards to what is currently considered best practice. EUROCRINE will be a key means by which the medical profession, researchers, health policy makers, and not least patients, can benefit from an increase in knowledge related to diagnosis, treatment, and future clinical research in the field of rare endocrine tumours.

02

Conditions studied

  • Endocrine Tumor

Keywords

  • adrenal
  • thyroid
  • parathyroid
  • endocrine pancreas
  • endocrine digestive tube
03

In context

Endocrine Gland Neoplasms

49 studies on the registry are indexed under Endocrine Gland Neoplasms; 14 are open to participants now.

This study's planned enrollment of 3,000 is above the median of 454 across 16 observational studies indexed under Endocrine Gland Neoplasms.

Browse Endocrine Gland Neoplasms studies →

Lead sponsor

Central Hospital, Nancy, France is the lead sponsor of 798 studies on the registry; 186 are open to participants now.

Browse Central Hospital, Nancy, France studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients who undergo surgical procedures for endocrine tumors at CHU Nancy Brabois (University hospital)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients who undergo surgical procedures for endocrine tumors at the University Nancy Brabois Hospital

Exclusion criteria

Exclusion Criteria:

  • unable to receive clear information
  • refusal to sign the consent form
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • registry of endocrine tumors

    * Patients who undergo thyroid surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-22. * Patients who undergo parathyroid surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-23 * Patients who undergo adrenal surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-24 * Patients who undergo pancreatic and digestive surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-26

06

What researchers measure

Primary outcomes

  1. Postoperative complications (endocrine surgical procedure)

    morbidity rate in percentage (%)

    Time frame: 12 months after surgical procedure

Secondary outcomes

  1. Postoperative complications severity (endocrine surgical procedure)

    Dindo-Clavien classification in percentage (%)

    Time frame: 12 months after surgical procedure

  2. Postoperative mortality (endocrine surgical procedure)

    mortality rate in percentage (%)

    Time frame: 12 months after surgical procedure

  3. CT imaging before endocrine surgical procedure (Tumor characteristics)

    Density in Hounsfield unit (HU)

    Time frame: Baseline

  4. CT imaging before endocrine surgical procedure (Coronary artery score)

    CAC score in Agatston score unit (HU)

    Time frame: Baseline

  5. CT imaging before endocrine surgical procedure (Sarcopenia)

    Evaluation of sarcopenia using L3 skeletal muscle index (in cm²/m²)

    Time frame: preoperative period

  6. Bone mineral density

    dual-energy x-ray absorptiometry (DEXA) (in T-score unit)

    Time frame: Baseline

  7. Intraoperative systolic arterial pressure

    systolic arterial pressure (in mmHg)

    Time frame: Intraoperative

  8. Intraoperative diastolic arterial pressure

    diastolic arterial pressure (in mmHg)

    Time frame: Intraoperative

  9. Parathormone plasma levels

    Parathormone (in pg/mL)

    Time frame: Baseline and up to 12 months after surgical procedure

  10. Aldosterone plasma levels

    Aldosterone (in pmol/L)

    Time frame: Baseline and up to 12 months after surgical procedure

  11. Plasma renin activity

    Renin (in μIU/mL)

    Time frame: Baseline and up to 12 months after surgical procedure

  12. Plasma free metanephrines

    metanephrines (in nmol/L)

    Time frame: Baseline and up to 12 months after surgical procedure

  13. PET scanning

    standardized uptake values (SUV tumor / SUV liver ratio)

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Remond A, Marciniak C, Lenne X, Chouraki V, Gobert M, Baud G, Maillard L, Bouriez D, Liekens E, Donatini G, Nomine-Criqui C, Ravenet A, Santucci N, Kuczma P, Bouviez N, Tresallet C, Mirallie E, Deguelte S, Brunaud L, Guerin C, Gronnier C, Lifante JC, Bruandet A, Theis D, Cortot A, Scherpereel A, Hamroun A, Pattou F, Caiazzo R. Survival and Prognostic Factors After Adrenalectomy for Secondary Malignancy: A Combined Analysis of a French University Center Registry (Eurocrine) of 307 Patients and a French Nationwide Study of 2515 Patients. Ann Surg. 2024 Nov 1;280(5):825-834. doi: 10.1097/SLA.0000000000006479. Epub 2024 Aug 7. PubMed 39109429 ↗
  • Greilsamer T, Nomine-Criqui C, Thy M, Ullmann T, Zarnegar R, Bresler L, Brunaud L. Robotic-assisted unilateral adrenalectomy: risk factors for perioperative complications in 303 consecutive patients. Surg Endosc. 2019 Mar;33(3):802-810. doi: 10.1007/s00464-018-6346-2. Epub 2018 Jul 11. PubMed 29998394 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2015 (actual). Primary completion is estimated for Jan 2030, 180 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2018
First posted
Jan 25, 2018
StartActual
Jan 1, 2015
Primary completionEst.
Jan 1, 2030
CompletionEst.
Jan 1, 2030
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 39109429 ↗
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 39109429 ↗
    + 4 other changes: verification date, responsible party, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03410394
Lead sponsor
Central Hospital, Nancy, France
Collaborators
Association Francophone de Chirurgie Endocrinienne (AFCE), European Society of Endocrine Surgery (ESES)
Responsible party
Laurent BRUNAUD (investigator, Central Hospital, Nancy, France) — Principal investigator
First posted
Jan 25, 2018
Start date
Jan 1, 2015
Primary completion
Jan 1, 2030 (estimated)
Completion
Jan 1, 2030 (estimated)
Last update
Oct 22, 2026

Study contacts

laurent Brunaud, MD, PhD
Contact
l.brunaud@chru-nancy.fr
Brunaud
Contact
l.brunaud@chru-nancy.fr
laurent Brunaud
principal investigator · University of Lorraine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Endocrine Gland Neoplasms →

Other studies from this sponsor

Central Hospital, Nancy, France →

Start the discussion